Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169:1053–60.
Article PubMed PubMed Central Google Scholar
Oliveira SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. BMJ (Clinical research ed.). 2017;357:j2083.
Dolinger M, Torres J, Vermeire S. Crohn’s disease. Lancet. 2024;403:1177–91.
Article CAS PubMed Google Scholar
Rogler G, Singh A, Kavanaugh A, et al. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161:1118–32.
Article CAS PubMed Google Scholar
Shield DE, Lytton B, Weiss RM, et al. Urologic complications of inflammatory bowel disease. J Urol. 1976;115:701–6.
Article CAS PubMed Google Scholar
Mutalib M. Renal involvement in pediatric inflammatory bowel disease. Pediatr Nephrol. 2021;36:279–85.
Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819–31.
Article CAS PubMed PubMed Central Google Scholar
Song Y, Huang X, Yu G, et al. Pathogenesis of IgA vasculitis: an up-to-date review. Front Immunol. 2021;12: 771619.
Article CAS PubMed PubMed Central Google Scholar
Leung AKC, Barankin B, Leong KF. Henoch-Schönlein purpura in children: an updated review. Curr Pediatr Rev. 2020;16:265–76.
Xu L, Li Y, Wu X. IgA vasculitis update: epidemiology, pathogenesis, and biomarkers. Front Immunol. 2022;13: 921864.
Article CAS PubMed PubMed Central Google Scholar
Stamellou E, Seikrit C, Tang SCW, et al. IgA nephropathy. Nat Rev Dis Primers. 2023;9:67.
Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402–14.
Article CAS PubMed Google Scholar
Willey CJ, Coppo R, Schaefer F, et al. The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transplant. 2023;38:2340–9.
Article PubMed PubMed Central Google Scholar
Shibano T, Takagi N, Maekawa K, et al. Epidemiological survey and clinical investigation of pediatric IgA nephropathy. Clin Exp Nephrol. 2016;20:111–7.
Article CAS PubMed Google Scholar
Cheung CK, Barratt J. Further evidence for the mucosal origin of pathogenic IgA in IgA nephropathy. J Am Soc Nephrol. 2022;33:873–5.
Article CAS PubMed PubMed Central Google Scholar
He JW, Zhou XJ, Lv JC, et al. Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies. Theranostics. 2020;10:11462–78.
Article CAS PubMed PubMed Central Google Scholar
Gesualdo L, Di Leo V, Coppo R. The mucosal immune system and IgA nephropathy. Semin Immunopathol. 2021;43:657–68.
Article CAS PubMed PubMed Central Google Scholar
Kovács T, Kun L, Schmelczer M, et al. Do intestinal hyperpermeability and the related food antigens play a role in the progression of IgA nephropathy? I Study of intestinal permeability. Am J Nephrol. 1996;16:500–5.
Wyatt J, Vogelsang H, Hübl W, et al. Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet. 1993;341:1437–9.
Article CAS PubMed Google Scholar
Kamei K, Ogura M, Sato M, et al. Evolution of IgA nephropathy into anaphylactoid purpura in six cases–further evidence that IgA nephropathy and Henoch-Schonlein purpura nephritis share common pathogenesis. Pediatr Nephrol. 2016;31:779–85.
Sy A, Khalidi N, Dehghan N, et al. Vasculitis in patients with inflammatory bowel diseases: a study of 32 patients and systematic review of the literature. Semin Arthritis Rheum. 2016;45:475–82.
Rasmussen C, Abitbol V, El Karoui K, et al. IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-α blockers. Rheumatology (Oxford). 2022;61:1957–65.
Article CAS PubMed Google Scholar
Hokama A, Sonosaki T, Zamami R, et al. Crohn disease complicated by IgA vasculitis during therapy with tumor necrosis factor-α inhibitor. Pol Arch Intern Med. 2019;129:283–4.
Li X, Wang Y, Ge T, et al. Henoch-Schönlein purpura associated with infliximab therapy for pediatric Crohn’s disease. Eur J Gastroenterol Hepatol. 2021;33:e1074–5.
Article CAS PubMed Google Scholar
Marques I, Lagos A, Reis J, et al. Reversible Henoch-Schönlein purpura complicating adalimumab therapy. J Crohns Colitis. 2012;6:796–9.
Nakayama T, Kaneko H, Okada A, et al. Association of inflammatory Bowel Disease with incident immunoglobulin a nephropathy. Clin J Am Soc Nephrol. 2024;19:704–11.
Yandian F, Caravaca-Fontán F, Herrera Hernandez LP, et al. Kidney diseases associated with inflammatory Bowel Disease: impact of chronic histologic damage, treatments, and outcomes. Kidney Int Rep. 2023;9:383–94.
Article PubMed PubMed Central Google Scholar
Graziano F, Busè M, Cassata N, et al. IgA nephropathy in a child: Crohn’s disease-associated or adalimumab induced? Curr Med Res Opin. 2022;38:139–43.
Terasaka T, Uchida HA, Umebayashi R, et al. The possible involvement of intestine-derived IgA1: a case of IgA nephropathy associated with Crohn’s disease. BMC Nephrol. 2016;17:122.
Article PubMed PubMed Central Google Scholar
Choi JY, Yu CH, Jung HY, et al. A case of rapidly progressive IgA nephropathy in a patient with exacerbation of Crohn’s disease. BMC Nephrol. 2012;13:84.
Article PubMed PubMed Central Google Scholar
Yang Z, Xu X, Dong Y, et al. The pathological and outcome characteristics of renal lesions in Crohn’s disease. BMC Nephrol. 2022;23:256.
Article CAS PubMed PubMed Central Google Scholar
Rehnberg J, Symreng A, Ludvigsson JF, et al. Inflammatory Bowel Disease is more common in patients with IgA nephropathy and predicts progression of ESKD: a Swedish population-based Cohort Study. J Am Soc Nephrol. 2021;32:411–23.
Article CAS PubMed Google Scholar
Knoop T, Vikse BE, Mwakimonga A, et al. Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol Dial Transplant. 2017;32:1841–50.
Comments (0)